Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases.

CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology ...

WHIPPANY, N.J., May 28, 2025--ASCO 2025: XOFIGO® Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases ...

Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

The addition of six cycles of radium-223 to first-line enzalutamide extended radiographic PFS for men with metastatic castration-resistant prostate cancer, according to results of a randomized ...

RPT dosimetry, including time activity curve fitting, was performed using the S-value-based Rapid 3D-RD-S software, accounting for the full decay chain of Ra-223.

Researchers have found a way to predict which patients are likely to respond to radium-223, a standard treatment for advanced prostate cancer that has spread to the bones.

Researchers seeking to improve the use of radium-223 to target cancer cells investigated how the isotope interacts with two chelators, macropa and DOTA. Experiments and computer-driven models ...

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.

For instance, a SPECT imaging system for αRPT would ideally require a superior energy resolution to discriminate energy peaks from the complex decay chain of the alpha-emitters involved, such as ...